Topic: targeted cancer drugs
South Korea’s Yuhan has licensed its lung cancer drug lazertinib to Janssen Biotech for $50 million upfront and another $1.2 billion in milestones.
Loxo is preparing for a November verdict from the FDA on larotrectinib as a treatment for solid tumors with NTRK fusions.
Phase 3 results with Daiichi Sankyo's new FLT3 inhibitor quizartinib put it on course for regulatory filings in acute myeloid leukemia.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets.
The FDA is working on a medical innovation development plan to lower healthcare costs by streamlining the path to market for targeted therapies.
In a late-stage study presented at ASCO, Chi-Med’s fruquintinib showed it could help relapsed patients with advanced colorectal cancer live longer.
British researchers kicked up some buzz at the American Society of Clinical Oncology annual meeting on June 3 with positive results from a phase 1 trial in ovarian cancer.
Deciphera Pharmaceuticals will head to ASCO this week with a spring in its step after raising $52 million in a third-round financing.
TP Therapeutics has the funds on hand to take its drug for resistant cancer through the next stages of clinical development after raising $45 million in a series C financing.